CRCP
SUPN icon

Copper Rock Capital Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Copper Rock Capital Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-502,683
Closed -$29.3M – 93
2018
Q2 		$29.3M Sell
502,683
-30,648
-6% -$1.59M 1.69% 14
2018
Q1 		$24.4M Buy
+533,331
New +$22.3M 1.46% 36

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Copper Rock Capital Partners's SUPN Position: Q3 2018 in Review

Copper Rock Capital Partners sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 502,683 shares — an estimated $29.3M sold.

Copper Rock Capital Partners first reported a position in SUPN in Q1 2018 and held it in 2 quarters. The position peaked at $29.3M in Q2 2018. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

  • Copper Rock Capital Partners reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Copper Rock Capital Partners sold 502,683 Supernus Pharmaceuticals shares in Q3 2018, an estimated $29.3M.
  • Copper Rock Capital Partners first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Copper Rock Capital Partners's Supernus Pharmaceuticals position peaked at $29.3M in Q2 2018.
  • 288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on Copper Rock Capital Partners's 13F filing for Q3 2018, filed 5 Oct 2018.